Affinity selection‐mass spectrometry in the discovery of anti‐SARS‐CoV‐2 compounds
- 5 August 2022
- journal article
- review article
- Published by Wiley in Mass Spectrometry Reviews
- Vol. 43 (1) , 39-46
Abstract
Small molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), which is the cause of the COVID‐19 pandemic. To expedite the discovery of lead compounds for development, assays have been developed based on affinity selection‐mass spectrometry (AS‐MS), which enables the rapid screening of mixtures such as combinatorial libraries and extracts of botanicals or other sources of natural products. AS‐MS assays have been used to find ligands to the SARS‐CoV‐2 spike protein for inhibition of cell entry as well as to the 3‐chymotrypsin‐like cysteine protease (3CLpro) and the RNA‐dependent RNA polymerase complex constituent Nsp9, which are targets for inhibition of viral replication. The AS‐MS approach of magnetic microbead affinity selection screening has been used to discover high‐affinity peptide ligands to the spike protein as well as the hemp cannabinoids cannabidiolic acid and cannabigerolic acid, which can prevent cell infection by SARS‐CoV‐2. Another AS‐MS method, native mass spectrometry, has been used to discover that the flavonoids baicalein, scutellarein, and ganhuangenin, can inhibit the SARS‐CoV‐2 protease 3CLpro. Native mass spectrometry has also been used to find an ent‐kaurane natural product, oridonin, that can bind to the viral protein Nsp9 and interfere with RNA replication. These natural lead compounds are under investigation for the development of therapeutic agents to prevent or treat SARS‐CoV‐2 infection.Keywords
This publication has 21 references indexed in Scilit:
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Development of a Magnetic Microbead Affinity Selection Screen (MagMASS) Using Mass Spectrometry for Ligands to the Retinoid X Receptor-αJournal of the American Society for Mass Spectrometry, 2016
- Magnetic Microbead Affinity Selection Screening (MagMASS) of Botanical Extracts for Inhibitors of 15-LipoxygenaseJournal of Natural Products, 2016
- Native Mass Spectrometry in Fragment-Based Drug DiscoveryMolecules, 2016
- ACE2 Cell Biology, Regulation, and Physiological Functions2015
- Development of a Screening Assay for Ligands to the Estrogen Receptor Based on Magnetic Microparticles and LC-MSCombinatorial Chemistry & High Throughput Screening, 2008
- Evaluation of Estrogenic Activity of Plant Extracts for the Potential Treatment of Menopausal SymptomsJournal of Agricultural and Food Chemistry, 2001
- Screening Solution-Phase Combinatorial Libraries Using Pulsed Ultrafiltration/Electrospray Mass SpectrometryJournal of Medicinal Chemistry, 1997
- Using Electrospray Ionization FTICR Mass Spectrometry To Study Competitive Binding of Inhibitors to Carbonic AnhydraseJournal of the American Chemical Society, 1995
- Bio‐affinity characterization mass spectrometryRapid Communications in Mass Spectrometry, 1995